George C. Prendergast

George C. Prendergast (born 1961) is an American biomedical scientist whose research has focused on cancer pathobiology and immunotherapy. His team pioneered development of drugs that inhibit the tryptophan catabolizing enzyme IDO1 as a new type of cancer immunotherapy, currently under study worldwide. Since 2004, he is President and CEO of Lankenau Institute for Medical Research.[1] Since 2006, he is also co-director of the Program in Cancer Cell Biology & Signaling at Kimmel Cancer Center, Thomas Jefferson University;.[2] From 2010-2017, Prendergast was Editor-in-Chief of Cancer Research, a journal of the American Association for Cancer Research.

George C. Prendergast
Born
Philadelphia, Pennsylvania
Alma materPrinceton University
Yale University
University of Pennsylvania
Awards1995 Pew Scholar in the Biomedical Sciences
Scientific career
FieldsOncology, Molecular biology, Oncoimmunology
InstitutionsLankenau Institute for Medical Research
DuPont Pharmaceuticals Company
The Wistar Institute
Merck Research Laboratories
Howard Hughes Medical Institute

Selected publications
  • Prendergast, GC; Malachowski, WP; DuHadaway, JB; Muller, AJ (2017). "Discovery of IDO1 inhibitors: from bench to bedside". Cancer Research. 77 (24): 6795. doi:10.1158/0008-5472.CAN-17-2285. PMID 29247038.
  • Prendergast; GC (2011). "Why tumours eat tryptophan". Nature. 478 (7368): 192. doi:10.1038/478192a. PMID 21993754.
  • Muller, AJ; Duhadaway, JB; Donover, PS; Sutanto-Ward, E; Prendergast, GC (2005). "Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy". Nature Medicine. 11 (3): 312. doi:10.1038/nm1196. PMID 15711557.
  • Sakamuro, D; Elliott, KJ; Wechsler-Reya, R; Prendergast, GC (1996). "BIN1 is a novel MYC-interacting protein with features of a tumour suppressor". Nature Genetics. 14 (1): 69. doi:10.1038/ng0996-69. PMID 8782822.
  • Prendergast, G; Ziff, E (1991). "Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region". Science. 251 (4990): 186. Bibcode:1991Sci...251..186P. doi:10.1126/science.1987636. PMID 1987636.
  • Prendergast, GC; Lawe, D; Ziff, EB (1991). "Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation". Cell. 65 (3): 395. doi:10.1016/0092-8674(91)90457-A. PMID 1840505.

References
  1. "The Lankenau Institute for Medical Research - George C. Prendergast, PhD". Retrieved 29 December 2013.
  2. Program in Cancer Cell Biology & Signaling, Kimmel Cancer Center, Thomas Jefferson University
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.